New biological treatments for asthma and skin allergies.
Allergy 75, 546-560 (2020)
Allergies are typically endemic, complex and heterogeneous diseases with a high impact at quality of life. Mechanistically, type 2 immune responses involving eosinophil and basophil granulocytes, mast cells and humoral factors such as IgE are key drivers of allergic diseases. Fighting allergic diseases knows three strategies: prevention, symptomatic and causative therapy. While remarkable progress was made in understanding molecular events in allergies as a prerequisite for effective prevention and desensitization, this review article focuses on the most efficient symptomatic treatments-that is using more and more specific antibodies neutralizing particular immune pathways. We highlight and classify recent and upcoming developments in the three prototype chronic allergic diseases allergic asthma, chronic spontaneous urticaria and atopic eczema. In all three examples, biologics such as dupilumab or omalizumab become reliable and efficient therapeutic options. Finally, we give an outlook how a diagnostic and therapeutic workflow might look like in the near future for these three major burdens of society.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Review
Thesis type
Editors
Keywords
Asthma ; Atopic Dermatitis ; Endotype ; Skin Allergy ; Treatment ; Urticaria; Chronic Spontaneous Urticaria; Humanized Monoclonal-antibody; Anti-cd20 Rituximab Treatment; Eczema Atopic-dermatitis; Eosinophilic Asthma; Double-blind; European Guidelines; Qge031 Ligelizumab; Global Burden; In-vitro
Keywords plus
Language
english
Publication Year
2020
Prepublished in Year
2019
HGF-reported in Year
2019
ISSN (print) / ISBN
0105-4538
e-ISSN
1398-9995
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 75,
Issue: 3,
Pages: 546-560
Article Number: ,
Supplement: ,
Series
Publisher
Wiley
Publishing Place
111 River St, Hoboken 07030-5774, Nj Usa
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30202 - Environmental Health
Research field(s)
Allergy
PSP Element(s)
G-505490-001
Grants
Copyright
Erfassungsdatum
2020-01-13